OSR Health (OSRH) Research & Development (2024 - 2025)
OSR Health's (OSRH) quarterly Research & Development came in at -$1794.0 in Q3 2025, down 103.28% year-over-year from $54705.0 in Q3 2024, and down 103.35% quarter-over-quarter from $53525.0 in Q2 2025.
Powered by 
Analysis
OSR Health (OSRH) Research & Development (2024 - 2025) Analysis & Trends
OSR Health has disclosed Research & Development across 2 years of filings, most recently posting -$1794.0 for Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 202.02 Mn |
| 10 | OSR Health | 6.59 Mn | 4.94 Mn | 86,605.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -1,794.00 |
| Jun 30, 2025 | 53,525.00 |
| Mar 31, 2025 | 90,149.00 |
| Sep 30, 2024 | 54,705.00 |
| Jun 30, 2024 | 45,259.00 |
| Mar 31, 2024 | 46,715.00 |